TY - JOUR
T1 - In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression
T2 - Early kinetics of radiolabelled FIAU
AU - Haubner, Roland
AU - Avril, Norbert
AU - Hantzopoulos, Petros A.
AU - Gansbacher, Bernd
AU - Schwaiger, Markus
N1 - Funding Information:
Acknowledgements. We thank Kai Borchers, Claudia Kolligs and Josef Lang for excellent technical assistance. We would also like to acknowledge Dr. Ronald Blasberg (Memorial Sloan-Kettering Cancer Center, New York) for his cooperation and Dr. Ronald Finn (Memorial Sloan-Kettering Cancer Center, New York) for his advice regarding the FIAU synthesis. This work was supported by the Deutsche Forschungsgemeinschaft (SFB 456) and by the KKF grant F65-98.
PY - 2000
Y1 - 2000
N2 - Previous studies have shown that the herpes simplex virus type 1 thymidine kinase gene (HSV1-tk), in combination with appropriate radiolabelled substrates (e.g. [I*]-2'-fluoro-2'-deoxy-5-iodo-1-β-D- arabinofuranosyluracil; I*-FIAU, where the asterisk indicates that any of the various radioactive iodine isotopes can be used), can be used as a reporter gene for in vivo monitoring of gene transfer and expression. The aim of our study was to examine the early kinetics of I*-FIAU and the possibility of utilising iodine-123-labelled FIAU for imaging of gene expression. CMS-5 fibrosarcoma cells were transduced in vitro with the retroviral vector STK containing the HSV1-tk gene. BALB/c mice were inoculated subcutaneously with HSV1-tk(+) and tk(-) cells into both flanks. FAU (2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyluracil was radioiodinated (123I, 125I) using the iodogen method. High-performance liquid chromatography purification resulted in high specific activity and radiochemical purity for both tracers ([123I]FIAU and [125I]FIAU). Biodistribution studies and gamma camera imaging were performed at 0.5, 1,2 and 4 h p.i. In addition, the genomic DNA of the tumours was isolated for measurement of the activity accumulation resulting from the [125I]FIAU incorporation. Biodistribution studies 0.5 h p.i. showed tumour/blood and tumour/muscle ratios of 3.8 and 7.2, respectively, for the HSV1-tk(+) tumours, and 0.6 and 1.2, respectively, for negative control tumours. Fast renal elimination of the tracer from the body resulted in rapidly increasing tumour/blood and tumour/muscle ratios which reached values of 32 and 88 at 4 h p.i., respectively. Tracer clearance from blood was bi-exponential, with an initial half-life of 0.6 h followed by a half-life of 4.6 h. The tracer half- life in herpes simplex viral thymidine kinase-expressing tumours was 35.7 h. The highest activity accumulation (20.3% ± 5.7% ID/g) in HSV1-tk(+) tumours was observed 1 h p.i. At that time, about 46% of the total activity found in HSV1-tk(+) tumours was incorporated into genomic DNA. Planar gamma camera imaging showed a distinct tracer accumulation as early as 0.5 h p.i., with an increase in contrast over time. These results suggest that sufficient tumour/background ratios for in vivo imaging of HSV1-tk expression with [123I]FIAU are reached as early as I h p.i.
AB - Previous studies have shown that the herpes simplex virus type 1 thymidine kinase gene (HSV1-tk), in combination with appropriate radiolabelled substrates (e.g. [I*]-2'-fluoro-2'-deoxy-5-iodo-1-β-D- arabinofuranosyluracil; I*-FIAU, where the asterisk indicates that any of the various radioactive iodine isotopes can be used), can be used as a reporter gene for in vivo monitoring of gene transfer and expression. The aim of our study was to examine the early kinetics of I*-FIAU and the possibility of utilising iodine-123-labelled FIAU for imaging of gene expression. CMS-5 fibrosarcoma cells were transduced in vitro with the retroviral vector STK containing the HSV1-tk gene. BALB/c mice were inoculated subcutaneously with HSV1-tk(+) and tk(-) cells into both flanks. FAU (2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyluracil was radioiodinated (123I, 125I) using the iodogen method. High-performance liquid chromatography purification resulted in high specific activity and radiochemical purity for both tracers ([123I]FIAU and [125I]FIAU). Biodistribution studies and gamma camera imaging were performed at 0.5, 1,2 and 4 h p.i. In addition, the genomic DNA of the tumours was isolated for measurement of the activity accumulation resulting from the [125I]FIAU incorporation. Biodistribution studies 0.5 h p.i. showed tumour/blood and tumour/muscle ratios of 3.8 and 7.2, respectively, for the HSV1-tk(+) tumours, and 0.6 and 1.2, respectively, for negative control tumours. Fast renal elimination of the tracer from the body resulted in rapidly increasing tumour/blood and tumour/muscle ratios which reached values of 32 and 88 at 4 h p.i., respectively. Tracer clearance from blood was bi-exponential, with an initial half-life of 0.6 h followed by a half-life of 4.6 h. The tracer half- life in herpes simplex viral thymidine kinase-expressing tumours was 35.7 h. The highest activity accumulation (20.3% ± 5.7% ID/g) in HSV1-tk(+) tumours was observed 1 h p.i. At that time, about 46% of the total activity found in HSV1-tk(+) tumours was incorporated into genomic DNA. Planar gamma camera imaging showed a distinct tracer accumulation as early as 0.5 h p.i., with an increase in contrast over time. These results suggest that sufficient tumour/background ratios for in vivo imaging of HSV1-tk expression with [123I]FIAU are reached as early as I h p.i.
KW - Gene therapy
KW - HSV1-tk
KW - Imaging
KW - Radiolabelled FIAU
UR - http://www.scopus.com/inward/record.url?scp=0034073577&partnerID=8YFLogxK
U2 - 10.1007/s002590050035
DO - 10.1007/s002590050035
M3 - Article
C2 - 10774880
AN - SCOPUS:0034073577
SN - 0340-6997
VL - 27
SP - 283
EP - 291
JO - European Journal of Nuclear Medicine
JF - European Journal of Nuclear Medicine
IS - 3
ER -